BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Jan 2018
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- Acronyms COMBI-MB
- Sponsors GlaxoSmithKline; Novartis; Novartis Pharma A.G.
- 05 Jan 2018 This trial has been completed in Spain
- 04 Dec 2017 Planned End Date changed from 15 Dec 2017 to 16 Jan 2018.
- 02 Oct 2017 Planned End Date changed from 30 Sep 2017 to 15 Dec 2017.